Cancer Research · 2011 · 97 citations · 36 references
MedicineOncologyPharmacologyApoptosisDrug DiscoveryMolecular OncologyTargeted Cancer TherapyTargeted TherapyAnnexin V AssaysAnticancer ActivityCancer Cell Proliferation InhibitionCancer Targeting LigandsCell Surface ProteinsMolecularly Targeted AgentsTumor Targeting LigandsTumor-targeted Ligands
Recent studies have implicated the involvement of cell surface forms of nucleolin in tumor growth. In this study, we investigated whether a synthetic ligand of cell-surface nucleolin known as N6L could exert antitumor activity. We found that N6L inhibits the anchorage-dependent and independent growth of tumor cell lines and that it also hampers angiogenesis. Additionally, we found that N6L is a proapoptotic molecule that increases Annexin V staining and caspase-3/7 activity in vitro and DNA fragmentation in vivo. Through affinity isolation experiments and mass-spectrometry analysis, we also identified nucleophosmin as a new N6L target. Notably, in mouse xenograft models, N6L administration inhibited human tumor growth. Biodistribution studies carried out in tumor-bearing mice indicated that following administration N6L rapidly localizes to tumor tissue, consistent with its observed antitumor effects. Our findings define N6L as a novel anticancer drug candidate warranting further investigation.
36
Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth
Michael S. O’Reilly, Thomas Boehm, Yuen Shing et al. · Cell · 1997 · 4.5K citations · Full text
Medicine, Oncology, Pharmacology +11
Apoptosis, oncosis, and necrosis. An overview of cell death.
Guido Majno, I Joris · PubMed · 1995 · 3.3K citations
Endostatin Induces Endothelial Cell Apoptosis
Mohanraj Dhanabal, Ramani Ramchandran, Matthew J.F. Waterman et al. · Journal of Biological Chemistry · 1999 · 584 citations · Full text